Amorfix Licenses Novel Theranostic Platform - ProMIS(TM) - For Predicting Protein Misfolding

    - Platform Predicts Novel Therapeutic and Diagnostic Targets -

    TSX: AMF

    TORONTO, June 17 /CNW/ - Amorfix Life Sciences (TSX:AMF), a company
focused on treatments and diagnostics for misfolded protein diseases announces
it has licensed the exclusive rights to the ProMIS(TM) target identification
technology from the University of British Columbia (UBC), to predict novel
Disease Specific Epitopes (DSE) on the molecular surface of misfolded
    "The ProMIS(TM) target identification technology is a breakthrough method
to model virtually any protein and predict how it will misfold," said Dr.
George Adams, CEO of Amorfix. "PROMIS(TM) has already been used to identify
potential DSE's on three known target proteins likely to be misfolded in
cancer and the development of novel immunotherapeutics and companion
diagnostics for these diseases has begun."
    ProMIS(TM) is an "in silico" rational selection approach that can be
applied to any protein where the normal folding structure is at least
partially known. There are 57,000 such protein structures currently available
in public databases. Amorfix is also exploring partnerships with other
companies to accelerate the development and expand its program to other
proteins of interest.
    The ProMIS(TM) target identification technology is the product of the
collaborative efforts of UBC scientists Neil Cashman, Will Guest and Steven
Plotkin. "Using this technology we plan to efficiently 'mine' the human
structural proteome and identify abnormally exposed DSE domains to develop
novel diagnostic disease markers and treatment targets", said Dr. Cashman, who
is also the Chief Scientific Officer at Amorfix.

    About Amorfix
    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting misfolded diseases
including neurodegenerative diseases and cancer. It has specific programs in
vCJD, ALS and Alzheimer's Disease. Amorfix's proprietary Epitope
Protection(TM) (EP) technology enables it to specifically identify very low
levels of aggregated misfolded proteins (AMP) in a sample containing normal
protein. Aggregated misfolded proteins are a common element of many
brain-wasting diseases, and more recent evidence points to misfolded proteins
being created in many cancers. Amorfix has shown antibodies and vaccines to
misfolded proteins are therapeutic in preclinical animal models. Amorfix's
lead programs are a diagnostic blood screening test for vCJD and a therapy for

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

    %SEDAR: 00022789E

For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890